id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-345611-xv62h83a	Cavalcanti, A. B.	Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial	2020-05-26		.txt	text/plain	4284	225	46	Methods and analysis: We describe the rationale and design of an open-label pragmatic multicentre randomised (concealed) clinical trial of 7 days of hydroxychloroquine (400 mg BID) plus azithromycin (500 mg once daily), hydroxychloroquine 400 mg BID, or standard of care for moderately severe hospitalised patients with suspected or confirmed COVID-19 (in-patients with up to 4L/minute oxygen supply through nasal catheter). The control group receive the current standard of care treatment for COVID-19, which includes daily monitoring with clinical assessment of the attending physician, routine laboratory tests (blood count, urea, creatinine, liver enzymes and bilirubin, c-reactive protein) at the discretion of the attending physician, respiratory and motor physiotherapy, surveillance of vital parameters according to the patient's location (inpatient unit and ICU), at least once per period, which may be more frequent CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	./cache/cord-345611-xv62h83a.txt	./txt/cord-345611-xv62h83a.txt